The CenterWatch Monthly, August 2011

Monday, August 1, 2011 08:26 AM

Sponsors target new areas to speed cycle times

Biopharmaceutical company executives struggle to find ways of shortening drug development cycle time. Sponsors place a high priority on accelerating cycle time to help improve R&D productivity, yet median cycle times, according to analysis of FDA and industry data, increased by nearly 15% between 1994 and 2009, from 77.3 to 81.9 months. Executives say the greatest challenge to reducing cycle time is the large, phase III clinical trial, which has become more complex. Yet overall, these executives say the most promising areas for improving cycle times are...

Anticipating new clinical trials business for biosimilars

Pharmaceutical companies that once scoffed at generics are getting ready to enter a new business: making copycat version of expensive biotechnology drugs, often with required clinical trials, to fill their dwindling drug pipelines. And they are not alone, as biotech companies are also pursuing the fledgling biosimilar market that has sprouted in Europe. Now there are early signs of an FDA regulatory pathway specifically for biosimilar development...

Eye On Novo Nordisk

Novo Nordisk, a global healthcare company headquartered in Denmark, opened in 1923. In addition to pursuing pharmacotherapy for diabetes and other Endocrinology indications, Novo Nordisk is in active development of drug candidates in Hematology and Inflammation...

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs